Durysta Implant
Product Images NDC 0023-9652

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Durysta (NDC 0023-9652). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Allergan, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1 (Durysta 01)

Illustration of the DURYSTA intracameral implant applicator showing a safety cap, safety tab, and an actuator button on the device. The diagram indicates removal of the safety components prior to use, highlighting parts of the implant delivery system for bimatoprost 10 micrograms.*

FDA Label Image

Figure 2 (Durysta 02)

An instructional illustration showing an eye with a needle approaching the corneal area, indicating the intracameral route of administration. The image is related to DURYSTA bimatoprost 10 mcg implant, depicting the method of implant insertion into the anterior chamber of the eye.*

FDA Label Image

The Chemical Name For Bimatoprost Is (z)-7-[(1r,2r,3r,5s)-3,5-dihydroxy-2-[(1e,3s)-3-hydroxy-5-phenyl-1-pentenyl]cyclopentyl]-n-ethyl-5-heptenamide, And Its Molecular Weight Is 415.57. Its Molecular Formula Is C25h37no4. (Durysta 03)

Chemical structure of bimatoprost, the active ingredient in DURYSTA 10 ug implant. The diagram illustrates the molecular configuration with distinct functional groups and stereochemistry.*

FDA Label Image

Figure 3 (Durysta 04)

A line graph comparing intraocular pressure (IOP) in mmHg over time between DURYSTA (bimatoprost implant) and Timolol treatments. The graph shows data points at Hour 0 and Hour 2 during Weeks 2, 6, 12, and 15, illustrating the changes in IOP measurements for both treatments with DURYSTA represented by blue lines and Timolol by green dashed lines.*

FDA Label Image

Figure 4 (Durysta 05)

A line graph comparing intraocular pressure (IOP) measurements over time for DURYSTA implant and Timolol treatment. The graph shows IOP values at baseline and 2 hours post-treatment across weeks 2, 6, 12, and 15, highlighting mean values and 95% confidence intervals for both treatments.*

FDA Label Image

Abbvie Logo (Durysta 06)

FDA Label Image

Principal Display Panelndc 0023-9652-01durysta® (bimatoprost Intracameral Implant) 10 Mcgone Sterile, Single-dose Applicatorfor Intracameral Administrationrx Only (Durysta 07)

Packaging label for DURYSTA (bimatoprost intracameral implant) 10 mcg by Allergan, Inc. The label shows the product name, dosage strength of 10 mcg, and that it is for intracameral administration. It specifies a sterile, single-dose applicator and includes the NDC 0023-9652. The label is primarily green with white and yellow text.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.